External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ACG 2026
Roche and Genentech at

ACG 2026

October 09 - October 14
Nashville, USA
acgmeetings.gi.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:30 PM
Duration 210mins Nashville, USA
Indirect Comparison of Afimkibart and Adalimumab Treatment Effects Using Data From TUSCANY-2 and HIBISCUS in Patients With Ulcerative Colitis
Dubinsky M, Xu Q, Manickam VA, Li Y, Levitte S, Zhang J, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Vincent MS, Park KT
Gastroenterology | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 345mins Nashville, USA
Functional Advantage of Afimkibart’s Preference for Trimeric TL1A in Blocking Active TL1A Signaling
Fuh F, Varfolomeev E, Nguyen A, Oh A, Tao X, Lasch K, Neighbors M, Mohanann V, Vucic D
Gastroenterology | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 345mins Nashville, USA
Real-World Treatment Patterns in Patients with Moderate to Severe Ulcerative Colitis in the United States
Johnson A, Patel A, Schuldt R, Fehlmann T, Kostiuk B, Yau V, Win N, Reilly N, Zurek O, Shapouri S
Gastroenterology | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 345mins Nashville, USA
Symptomatic Remission and Health-Related Quality of Life With Afimkibart Treatment for Moderately to Severely Active Ulcerative Colitis in the Phase 2b TUSCANY-2 Trial
Allegretti JR, Yarur A, Leong RW, Danese S, Peyrin-Biroulet L, Bojic D, Lasch K, Schiffman C, Pei J, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Vincent MS, Jairath V
Gastroenterology | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 345mins Nashville, USA
A Patient-Centric Evolution: Trial Design in Inflammatory Bowel Disease Clinical Trials
Sands BE, Dulai PS, Peyrin-Biroulet L, Danese S, Jairath V, Hart AL, Regueiro MA, Kametas M, Ursos L, Schiffman C, Ertan-Ahmed S, Sadeghi M, Gomez M, Rubin DT
Gastroenterology | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.